Teva Pharmaceutical Industries (NYSE:TEVA) Issues Earnings Results, Beats Estimates By $0.14 EPS

Teva Pharmaceutical Industries (NYSE:TEVA) issued its earnings results on Tuesday. The company reported $0.86 EPS for the quarter, topping the consensus estimate of $0.72 by $0.14, FiscalAI reports. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%. The business had revenue of $4.39 billion during the quarter, compared to analysts’ expectations of $4.23 billion. During the same quarter last year, the firm posted $0.78 earnings per share. Teva Pharmaceutical Industries’s revenue was down 1.9% compared to the same quarter last year.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA opened at $40.84 on Tuesday. The stock has a market capitalization of $47.59 billion, a P/E ratio of 18.33, a P/E/G ratio of 3.71 and a beta of 0.89. Teva Pharmaceutical Industries has a 1-year low of $20.11 and a 1-year high of $42.59. The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 1.56. The business has a 50-day moving average price of $39.14 and a two-hundred day moving average price of $34.59.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q3 earnings beat expectations: Teva reported adjusted earnings of $0.86 per share, versus the $0.72 analyst consensus, while revenue of approximately $4.39 billion exceeded expectations of $4.23 billion. Revenue declined 1.9% year over year, but the earnings and sales beats provide support for the stock. Teva Pharmaceutical Q3 profit gain beats estimates
• Positive Sentiment: UZEDY momentum strengthened: U.S. net sales of the schizophrenia treatment reached $85 million in the third quarter, up 96% year over year. Teva raised its 2026 UZEDY revenue outlook to $290–$310 million from $270–$290 million, signaling stronger growth for a key branded product. Medincell UZEDY third-quarter sales and outlook
• Positive Sentiment: Biosimilar portfolio expanded: Teva signed an agreement with Samsung Bioepis to commercialize two FDA-approved U.S. immunology biosimilars. ETICOVO rights transfer upon closing, while infliximab-abda is expected to become available in the third quarter of 2027, supporting Teva’s generics and biosimilars strategy. Teva and Samsung Bioepis biosimilar agreement
• Positive Sentiment: Analyst endorsement: HC Wainwright initiated coverage with a “buy” rating and a $52 price target, implying meaningful potential upside from the referenced share price.
• Negative Sentiment: Neuroscience setback: Teva will discontinue the Phase 2 TOPAS-MSA study of emrusolmin for multiple system atrophy after an interim futility analysis indicated a low probability of meeting the primary efficacy endpoint. Although no safety concerns were identified, the decision removes a potential pipeline catalyst and was the primary source of selling pressure. Teva discontinues emrusolmin Phase 2 study

Insider Transactions at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 367,600 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $39.06, for a total transaction of $14,358,456.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Brian Savage sold 7,342 shares of the business’s stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $38.85, for a total transaction of $285,236.70. Following the sale, the insider directly owned 8,500 shares of the company’s stock, valued at approximately $330,225. This trade represents a 46.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 374,959 shares of company stock worth $14,644,285. Corporate insiders own 0.54% of the company’s stock.

Wall Street Analysts Forecast Growth

TEVA has been the subject of several research reports. Zacks Research cut shares of Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. UBS Group raised their price target on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a report on Friday, September 4th. Wall Street Zen lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. TD Cowen initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Thursday, October 1st. They issued a “buy” rating and a $55.00 price objective for the company. Finally, HC Wainwright began coverage on Teva Pharmaceutical Industries in a report on Monday. They set a “buy” rating and a $52.00 price objective on the stock. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $46.54.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company is one of the world’s largest producers of generic medicines and develops, manufactures and distributes prescription products across a broad range of therapeutic areas.

Teva’s portfolio includes generic medicines, specialty pharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products. Its specialty medicines include treatments for neurological and movement disorders, respiratory conditions, migraine and other chronic diseases.